Clinical Remission After Therapeutic Apheresis in a Patient Suffering from Long Term Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Case Report. — CFSMEATLAS
Clinical Remission After Therapeutic Apheresis in a Patient Suffering from Long Term Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Case Report.
Burgard, Harald · International medical case reports journal · 2024 · DOI
Quick Summary
This case report describes one woman with ME/CFS for over 15 years who underwent a blood-cleaning treatment called double-filtration apheresis eight times over two years. After treatment, she experienced significant improvement in her fatigue, thinking problems, and other symptoms, with benefits that lasted over time. While this is promising, it is based on just one patient's experience and needs much larger studies to confirm whether this treatment works for others with ME/CFS.
Why It Matters
ME/CFS currently lacks approved disease-modifying treatments, making any report of sustained clinical improvement noteworthy for patients and researchers seeking new therapeutic approaches. This case generates a testable hypothesis about apheresis efficacy that could guide future controlled clinical trials, potentially offering hope for patients with severe, treatment-resistant disease.
Observed Findings
One 49-year-old female patient with 15+ years of ME/CFS showed sustained clinical remission after eight double-filtration apheresis sessions over 2 years.
Significant improvement in fatigue, neurological symptoms, and systemic symptoms was reported.
Quality of life improvements were maintained beyond the treatment period.
Previous therapeutic approaches had failed in this patient before apheresis.
Inferred Conclusions
Double-filtration apheresis may be an effective therapeutic tool for treating ME/CFS in select patients.
Apheresis may help remove pathogenic blood components contributing to ME/CFS symptoms.
Does apheresis benefit other ME/CFS patients, or was this response idiosyncratic to this individual?
What is the mechanism of action—which blood components does apheresis remove that improves ME/CFS symptoms?
How should patient selection criteria be defined to identify who might benefit from apheresis?
What This Study Does Not Prove
This study does not prove that apheresis works for ME/CFS broadly—it documents one patient's response without a control group, comparison treatment, or blinding. The improvement could result from natural variation, placebo effects, concurrent lifestyle changes, or other unmeasured factors rather than the treatment itself. Controlled trials with larger patient populations are essential before drawing clinical conclusions.